专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

AU1198002A Medicament for the protection against thrombotic diseases 未知
公开(公告)号：AU1198002A
公开(公告)日：2002-07-25
申请号：AU1198002
申请日：2002-01-22
申请人： NIESWANDT BERNHARD
发明人： NIESWANDT BERNHARD
IPC分类号： G01N33/50 , A61K39/395 , A61K45/00 , A61P7/02 , A61P9/10 , C07K16/28 , C12N5/10 , C12N15/02 , C12P21/08 , G01N33/53 , G01N33/566 , G01N33/577 , C12N5/12
摘要： A medicament for the protection against thrombotic diseases is described that comprises an active principle which induces irreversible inactivation or degradation of the collagen receptor on thrombocytes. Antibodies, especially the humanized monoclonal antibody JAQ1, are the preferred active principle. Further a diagnostic agent for the determination of the expression rate of the collagen receptor GPVI is disclosed which contains the labelled monoclonal or polyclonal antibody directed against the GPVI epitope, preferably as defined by JAQ1.

12. 发明申请

WO2010149664A1 CLEC-2 IS AN ESSENTIAL PLATELET ACTIVATING RECEPTOR IN HEMOSTASIS AND THROMBOSIS 审中-公开
标题翻译： CLEC-2是HEMOSTASIS和THROMBOSIS中的基础药物活化受体
公开(公告)号：WO2010149664A1
公开(公告)日：2010-12-29
申请号：PCT/EP2010/058840
申请日：2010-06-22
申请人： CSL Behring GmbH , Julius-Maximilians-Universität-Würzburg , NIESWANDT, Bernhard , MAY, Frauke
发明人： NIESWANDT, Bernhard , MAY, Frauke
IPC分类号： A61P7/02
CPC分类号： G01N33/5044 , A61K39/39541 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K2317/55 , C07K2319/30 , G01N2333/4724 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, for use in treating or preventing a disorder related to venous or arterial thrombus formation and to the use of such an inhibitor as a lead compound for developing a drug for treating or preventing a disorder related to venous or arterial thrombus formation. The present invention also relates to a method of treating and/or preventing a disorder related to venous or arterial thrombus formation comprising administering a pharmaceutically effective amount of an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及包含C型凝集素样受体2（CLEC-2）抑制剂或CLEC-2活化剂抑制剂的药物组合物，其各自诱导CLEC-2的不可逆失活或降解血小板和任选的药学上可接受的载体，赋形剂和/或稀释剂。此外，本发明涉及C型凝集素样受体2（CLEC-2）的抑制剂或CLEC-2的活化剂的抑制剂，其各自诱导血小板上的CLEC-2的不可逆失活或降解，用于治疗或预防与静脉或动脉血栓形成相关的病症，以及使用这种抑制剂作为引导化合物用于开发用于治疗或预防与静脉或动脉血栓形成相关的病症的药物。本发明还涉及治疗和/或预防与静脉或动脉血栓形成相关的病症的方法，其包括给予药学有效量的C型凝集素样受体2（CLEC-2）抑制剂或 CLEC-2的活化剂，其各自诱导血小板上的CLEC-2的不可逆失活或降解，需要其受试者。本发明还涉及鉴定适合作为铅化合物的化合物和/或用于治疗和/或预防与静脉或动脉血栓形成相关的障碍的药物的方法。

13. 发明申请

WO2006066878A1 PREVENTION OF THROMBUS FORMATION AND/OR STABILIZATION 审中-公开
标题翻译：防止血栓形成和/或稳定
公开(公告)号：WO2006066878A1
公开(公告)日：2006-06-29
申请号：PCT/EP2005/013714
申请日：2005-12-20
申请人： NIESWANDT, Bernhard , RENNE, Thomas
发明人： NIESWANDT, Bernhard , RENNE, Thomas
IPC分类号： A61P7/02 , A61K39/395 , A61K38/56 , C07K16/36 , C07K14/81
CPC分类号： C07K16/36 , A61K38/55 , A61K38/556 , A61K38/56 , A61K38/57 , A61K39/3955 , A61K2039/505 , C07K16/40 , C07K2317/76 , Y02A50/414
摘要： The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of threedimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
摘要翻译：本发明涉及至少一种抗体和/或一种抑制剂用于抑制因子XII并防止三维血栓的形成和/或稳定化的用途。它还涉及药物制剂和使用因子XII作为抗血栓形成靶标。

14. 发明专利

AU784917B2 Medicament for the protection against thrombotic diseases 未知
公开(公告)号：AU784917B2
公开(公告)日：2006-07-27
申请号：AU1198002
申请日：2002-01-22
申请人： NIESWANDT BERNHARD
发明人： NIESWANDT BERNHARD
IPC分类号： A61K39/395 , G01N33/50 , A61K45/00 , A61P7/02 , A61P9/10 , C07K16/28 , C12N5/10 , C12N15/02 , C12P21/08 , G01N33/53 , G01N33/566 , G01N33/577
摘要： A medicament for the protection against thrombotic diseases is described that comprises an active principle which induces irreversible inactivation or degradation of the collagen receptor on thrombocytes. Antibodies, especially the humanized monoclonal antibody JAQ1, are the preferred active principle. Further a diagnostic agent for the determination of the expression rate of the collagen receptor GPVI is disclosed which contains the labelled monoclonal or polyclonal antibody directed against the GPVI epitope, preferably as defined by JAQ1.

15. 发明专利

ES2327604T3 MEDICAMENTO PARA PROTECCION CONTRA LAS ENFERMEDADES TROMBOTICAS. 未知
公开(公告)号：ES2327604T3
公开(公告)日：2009-11-02
申请号：ES01130953
申请日：2001-12-28
申请人： NIESWANDT BERNHARD
发明人： NIESWANDT BERNHARD
IPC分类号： A61K39/395 , G01N33/50 , A61K45/00 , A61P7/02 , A61P9/10 , C07K16/28 , C12N5/10 , C12N5/20 , C12N15/02 , C12P21/08 , G01N33/53 , G01N33/566 , G01N33/577
摘要： Medicamento para la protección contra enfermedades trombóticas, caracterizado porque comprende un anticuerpo, que induce una desactivación o degradación irreversible del receptor de colágeno en los trombocitos y se fija al mismo epítope del receptor de colágeno GPVI en los trombocitos que el anticuerpo monoclonal JAQ1, que puede obtenerse a partir de la línea de células de hibridoma con el número de depósito DSM ACC 2487.

16. 发明专利

CA2368791A1 MEDICAMENT FOR THE PROTECTION AGAINST THROMBOTIC DISEASES 未知
公开(公告)号：CA2368791A1
公开(公告)日：2002-07-23
申请号：CA2368791
申请日：2002-01-22
申请人： NIESWANDT BERNHARD
发明人： NIESWANDT BERNHARD
IPC分类号： G01N33/50 , A61K39/395 , A61K45/00 , A61P7/02 , A61P9/10 , C07K16/28 , C12N5/10 , C12N15/02 , C12P21/08 , G01N33/53 , G01N33/566 , G01N33/577
摘要： A medicament for the protection against thrombotic diseases is described th at comprises an active principle which induces irreversible inactivation or degradation of the collagen receptor on thrombocytes, Antibodies, especially the humanized monoclonal antibody JAQ1, are the preferred active principle. Further a diagnostic agent for the determination of the expression rate of t he collagen receptor GPVI is disclosed which contains the labelled monoclonal o r polyclonal antibody directed against the GPVI epitope, preferably as defined by JAQ1.

17. 发明申请

WO2010136577A1 STIM2-MEDIATED CAPACITIVE CALCIUM ENTRY 审中-公开
标题翻译： STIM2介导的电容钙入侵
公开(公告)号：WO2010136577A1
公开(公告)日：2010-12-02
申请号：PCT/EP2010/057443
申请日：2010-05-28
申请人： CSL BEHRING GMBH , JULIUS-MAXIMILIANS-UNIVERSITÄT-WÜRZBURG , NIESWANDT, Bernhard , STOLL, Guido
发明人： NIESWANDT, Bernhard , STOLL, Guido
IPC分类号： A61K39/395 , C07K16/18 , C12N15/113
CPC分类号： C07K16/18 , A61K39/39541 , C07K14/705
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations. The present invention also relates to a method of treating and/or preventing a neurological disorder associated with pathologically increased cytosolic calcium concentrations comprising administering a pharmaceutically effective amount of an inhibitor of STIM2 or of an inhibitor of STIM2-regulated plasma membrane calcium channel activity to a subject in need thereof. The present invention further relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations.
摘要翻译：本发明涉及包含STIM2抑制剂或STIM2调节的质膜钙通道活性抑制剂和任选的药学上可接受的载体，赋形剂和/或稀释剂的药物组合物。此外，本发明涉及用于治疗和/或预防与病理性增加的细胞溶质钙浓度相关的神经障碍的STIM2抑制剂或STIM2调节的质膜钙通道活性抑制剂。本发明还涉及治疗和/或预防与病理增加的细胞溶质钙浓度相关的神经障碍的方法，其包括将药物有效量的STIM2抑制剂或STIM2调节的质膜钙通道活性抑制剂施用于受到需要。本发明还涉及鉴定适合作为铅化合物的化合物和/或用于治疗和/或预防与病理增加的细胞溶质钙浓度相关的神经障碍的药物的方法。

18. 发明申请

WO2009129980A1 METHOD FOR THE PREVENTION AND TREATMENT OF CANCER BY INHIBITION OF GPVI 审中-公开
标题翻译：通过抑制GPVI预防和治疗癌症的方法
公开(公告)号：WO2009129980A1
公开(公告)日：2009-10-29
申请号：PCT/EP2009/002864
申请日：2009-04-20
申请人： CSL BEHRING GMBH , KRONTHALER, Ulrich , Nieswandt, Bernhard
发明人： KRONTHALER, Ulrich , Nieswandt, Bernhard
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/3053
摘要： The invention provides an inhibitor of GPVI for the prevention and or therapy of cancer and also the use of such an inhibitor of GPVI in the manufacture of a medicament for the prevention and/or therapy of cancer. A further aspect of the invention are pharmaceutical formulations comprising a GPVI inhibitor, which are suitable for the treatment of cancer, preferably for skin cancer, more preferably for melanoma, and most preferably for malignant cutaneous melanoma.
摘要翻译：本发明提供了用于预防和/或治疗癌症的GPVI抑制剂，以及GPVI抑制剂在制备用于预防和/或治疗癌症的药物中的用途。本发明的另一方面是包含GPVI抑制剂的药物制剂，其适用于治疗癌症，优选用于皮肤癌，更优选用于黑素瘤，最优选用于恶性皮肤黑素瘤。

19. 发明申请

WO2009115609A1 The calcium sensor STIM1 and the platelet SOC channel Orai1 (CRACM1) are essential for pathological thrombus formation 审中-公开
标题翻译：钙传感器STIM1和血小板SOC通道Orai1（CRACM1）对于病理性血栓形成至关重要
公开(公告)号：WO2009115609A1
公开(公告)日：2009-09-24
申请号：PCT/EP2009/053330
申请日：2009-03-20
申请人： CSL Behring GmbH , JULIUS-MAXIMILIANS UNIVERSITÄT WÜRZBURG , Braun, Attila , Kleinschnitz, Christoph , Nieswandt, Bernhard , Stoll, Guido , Varga-Szabó, Dávid
发明人： Braun, Attila , Kleinschnitz, Christoph , Nieswandt, Bernhard , Stoll, Guido , Varga-Szabó, Dávid
IPC分类号： A61K39/395 , A61P7/02
CPC分类号： C07K16/28 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0375 , A01K2267/0381 , C07K14/705 , C12N15/8509
摘要： The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1 ) or an inhibitor of STIM1 - regulated plasma membrane calcium channel activity, in particular an inhibitor of Oraii (also designated as CRACM1 ), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1 ) or an inhibitor of ST I M1 -regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1 ), for treating and/or preventing a disorder related to venous or arterial thrombus formation.
摘要翻译：本发明涉及一种药物组合物，其包含基质相互作用分子1（STIM1）抑制剂或STIM1调节的质膜钙通道活性抑制剂，特别是Oraii抑制剂（也称为CRACM1）和任选的药物活性物质载体，赋形剂或稀释剂。本发明还涉及基质相互作用分子1（STIM1）抑制剂或ST I M1调节性质膜钙通道活性抑制剂，特别是Orai1抑制剂（也称为CRACM1），用于治疗和/或预防与静脉或动脉血栓形成有关的紊乱。

20. 发明申请

WO2003103662A2 INHIBITORS OF GLYCOPROTEIN VI 审中-公开
标题翻译：葡萄糖苷VI的抑制剂
公开(公告)号：WO2003103662A2
公开(公告)日：2003-12-18
申请号：PCT/EP2003/005919
申请日：2003-06-05
申请人： PROCORDE GMBH , MASSBERG, Steffen , GAWAZ, Meinrad , NIESWANDT, Bernhard , BÜLTMANN, Andreas , MÜNCH, Götz , UNGERER, Martin , PELUSO, Mario , GRÜNER, Sabine
发明人： MASSBERG, Steffen , GAWAZ, Meinrad , NIESWANDT, Bernhard , BÜLTMANN, Andreas , MÜNCH, Götz , UNGERER, Martin , PELUSO, Mario , GRÜNER, Sabine
IPC分类号： A61K31/4035
CPC分类号： C07K14/745 , A61K38/00 , A61K47/6811 , A61K2039/505 , C07K14/70503 , C07K16/2803 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N2799/021 , G01N33/5088 , G01N33/86 , Y02A50/407
摘要： The Invention provides use of an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the prevention of intraarterial thrombosis in a Patient characterized by (i) having suffered from an acute coronary or carotid syndrome and (ü)having active intraarterial lesions. The present Invention also provides an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the manufacture of a medicament for the treatment of diabetes. Further, in vivo and in vivo screening methods for inhibitors or GP VI are provided and inhibitors identified thereby.
摘要翻译：本发明提供抗血小板糖蛋白VI（GPVI）的抗体用于制备用于预防患者动脉内血栓形成的药物，其特征在于：（i）患有急性冠状动脉或颈动脉综合征，和（ü）具有活动动脉内病变。本发明还提供了抗血小板糖蛋白VI（GPVI）的抗体，用于制备用于制备用于治疗糖尿病的药物的药物。此外，提供了用于抑制剂或GP VI的体内和体内筛选方法，由此鉴定出抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式